Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$23.4M Buy
93,109
+4,080
+5% +$878K 0.26% 77
2026
Q1
$19.4M Buy
89,029
+20,873
+31% +$4.63M 0.25% 76
2025
Q4
$15.6M Buy
68,156
+266
+0.4% +$60.6K 0.23% 82
2025
Q3
$15.7M Buy
67,890
+2,235
+3% +$455K 0.24% 80
2025
Q2
$12.2M Buy
65,655
+6,209
+10% +$1.15M 0.28% 64
2025
Q1
$12.5M Buy
59,446
+11,701
+25% +$2.27M 0.35% 55
2024
Q4
$8.48M Buy
47,745
+7,664
+19% +$1.41M 0.3% 60
2024
Q3
$7.92M Buy
40,081
+1,570
+4% +$293K 0.31% 57
2024
Q2
$6.61M Buy
38,511
+15,912
+70% +$2.64M 0.3% 57
2024
Q1
$4.12M Buy
22,599
+6,764
+43% +$1.17M 0.24% 53
2023
Q4
$2.45M Sell
15,835
-14,247
-47% -$2.08M 0.16% 88
2023
Q3
$4.48M Buy
30,082
+4,376
+17% +$642K 0.33% 43
2023
Q2
$3.46M Buy
25,706
+16,261
+172% +$2.38M 0.25% 54
2023
Q1
$1.51M Buy
9,445
+466
+5% +$71.2K 0.13% 82
2022
Q4
$1.45M Buy
8,979
+4,965
+124% +$761K 0.14% 82
2022
Q3
$539K Buy
4,014
+1,367
+52% +$196K 0.05% 163
2022
Q2
$405K Sell
2,647
-223
-8% -$34.1K 0.04% 168
2022
Q1
$465K Buy
2,870
+337
+13% +$49K 0.04% 182
2021
Q4
$343K Buy
+2,533
New +$299K 0.03% 200

Other funds holding ABBV

Summit Financial's ABBV Position: Q2 2026 in Review

Summit Financial increased its AbbVie (ABBV) stake by 4.6% in Q2 2026, buying an estimated $878K and bringing the position to 93,109 shares worth $23.4M. The position accounts for 0.26% of the portfolio, ranked #77.

Summit Financial first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. 4,224 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Summit Financial held 93,109 shares of AbbVie worth $23.4M as of Q2 2026.
  • Summit Financial bought 4,080 AbbVie shares in Q2 2026, an estimated $878K.
  • AbbVie made up 0.26% of Summit Financial's portfolio in Q2 2026, its #77 holding.
  • Summit Financial first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
  • 4,224 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Summit Financial's 13F filing for Q2 2026, filed 12 Aug 2026.